Advancing Novel CSF Biomarkers to Evaluate ALS Target Engagement & Improve Therapeutic Outcomes

Time: 9:30 am
day: Day One


  • CSF biomarkers interrogate multiple neuroinflammatory, neurodegenerative and neuroprotection pathways to confirm target engagement
  • Employing biomarkers at baseline and on-treatment in combination with clinical variables to predict clinical responders
  • Supporting biobanks and continuing dialogue with regulators to advance adoption of novel biomarkers